8-K - Movano Inc. (0001734750) (Filer)

NT 10-Q - Movano Inc. (0001734750) (Filer)

8-K - Movano Inc. (0001734750) (Filer)

424B5 - Movano Inc. (0001734750) (Filer)

10-K - Movano Inc. (0001734750) (Filer)

NT 10-K - Movano Inc. (0001734750) (Filer)

8-K - Movano Inc. (0001734750) (Filer)

10-Q - Movano Inc. (0001734750) (Filer)

8-K - Movano Inc. (0001734750) (Filer)

8-K - Movano Inc. (0001734750) (Filer)

PLEASANTON, Calif., May 23, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE)(the "Company") announced today that it received a notice (the "Notice") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") indicating that because the Company had not yet filed its Form 10-Q for the quarterly period ended March 31, 2025 (the "Form 10-Q"), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") requiring Nasdaq-listed companies to timely file all periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Form 10-Q was due on May 15, 2025.

PLEASANTON, Calif., May 16, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, announced today that its Board of Directors has initiated a process to explore strategic alternatives, including a sale, merger or similar transaction involving the Company, to maximize shareholder value.  To support this process, Movano Health's Board of Directors has engaged Aquilo Partners as its financial advisor and K&L Gates LLP as its legal counsel. There can be no assurance that this process will result in any transaction or other strategic change or as to the

Leveraging the Company's System-on-a-Chip (SoC), the clinical study results are another significant step forward in commercializing a cuffless, radio frequency (RF)-enabled blood pressure device PLEASANTON, Calif., April 22, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced positive results of its most recent 81-participant blood pressure clinical study. Movano Health's prototype demonstrated a level of accuracy well within the standards recognized by the FDA for blood pressure monitoring devices, achieving an overall mean absolute difference (MAD) of 4.9 mmHg, which significantly exceeds the 7 mmHg MAD threshold required per a standard for wea

Upgrades Also Include Integration with Apple Health, Manual Post-Workout Logging PLEASANTON, Calif., March 10, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology and maker of the Evie Ring, today announced a series of new data personalization, trend tracking and integration features on the ring's companion app that expand support for women's wellness journeys. The enhancements follow January's beta release of EvieAI, the first wearable-based virtual wellness assistant built exclusively with training data from medical journals. Available immediate

New proprietary RF hardware delivers significantly enhanced signal fidelity PLEASANTON, Calif., Feb. 4, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE) announced today that it has commenced a blood pressure clinical trial with its newly developed cuffless blood pressure wrist wearable. The study, which is expected to include at least 70 participants and be completed during the second week of February, utilizes the updated device to monitor pulse pressure waveforms in comparison with a hospital grade blood pressure device. The new wearable will also collect data on a host of other vital signs including pulse rate, blood oxygen saturation (SpO2), respiration rate and ECG waveforms.

Newest Evie Ring feature is the first medical journal trained AI companion in a wearable PLEASANTON, Calif., Jan. 8, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) today announced the latest enhancement to its Evie smart ring for women with the beta release of EvieAI, the first wearable-based virtual wellness assistant trained exclusively with data from medical journals. The new feature enables Evie users to answer health questions quickly, reliably and securely through the ring's companion app. Planned future integration with Evie data will allow EvieAI's responses to be p

PLEASANTON, Calif., Jan. 2, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced the expansion of its board of directors with the addition of Dr. Shaheen Wirk, a leader in healthcare dedicated investment with a track record of success in medicine, partnerships, and research. With over 20 years of investment experience in public and private life science companies, Dr. Wirk is the founder and Chief Investment Officer of Palkon Capital Management, a healthcare dedicated investment firm launched in partnership with Julian Robertson and

Company's first 510(k) clearance unlocks a TAM of $40 billion in healthcare B2B opportunities PLEASANTON, Calif., Dec. 2, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the pulse oximeter in its EvieMED Ring.  The clearance enables Movano Health to pursue multi-billion dollar business opportunities for health monitoring solutions needed for applications such as clinical trials, post-clinical trial management, and remote patient monitoring for both healthcare providers and payors.

Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Nov. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported third quarter 2024 results and provided a business update. The Company continues to remain focused on three key business initiatives. Successful execution of the Evie Ring direct-to-consumer business (D2C) following the September 17th back-in-sto

New hardware boasts significant improvements to reduce noise and generate higher fidelity signals PLEASANTON, Calif., Nov. 7, 2024 /PRNewswire/ -- Movano Health Inc. (NASDAQ:MOVE) announced today that it has tested its newly developed blood pressure wrist wearable as part of its November 5th and 6th hypoxia clinical trial that took place at the University of California, San Francisco. The updated device features an additional 12 mmWave antennas which together with Movano Health's custom IC delivers enhanced data collection with less impact of placement while also featuring a slimmer design, making it easier and more comfortable to wear. In addition, the new wearable monitors a host of other

4 - Movano Inc. (0001734750) (Issuer)

4 - Movano Inc. (0001734750) (Issuer)

4 - Movano Inc. (0001734750) (Issuer)

4 - Movano Inc. (0001734750) (Issuer)

4 - Movano Inc. (0001734750) (Issuer)

4 - Movano Inc. (0001734750) (Issuer)

4 - Movano Inc. (0001734750) (Issuer)

4 - Movano Inc. (0001734750) (Issuer)

Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Nov. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported third quarter 2024 results and provided a business update. The Company continues to remain focused on three key business initiatives. Successful execution of the Evie Ring direct-to-consumer business (D2C) following the September 17th back-in-sto

Prepares for September 17, 2024, Evie Ring back in stock dateAnnounces brand partnership with digital creator Heidi D'AmelioFocuses on launch of EvieMED and securing B2B opportunitiesConference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Aug. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported second quarter 2024 results and provided a business update. Following the successful close of the Company's April 2024 $24.1 million private placement that included a seed investment from a tier 1 multi-billion dollar medical device

Company continues to work with FDA to bring this pioneering healthcare product to market PLEASANTON, Calif., Aug. 5, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) plans to meet with the FDA in mid-August, as part of the Company's ongoing process to secure a 510(k) clearance for the EvieMED Ring, a wearable designed to not only provide medical device functionality through its pulse oximetry feature, but also offer numerous wellness metrics related to sleep, activity and mood/energy/symptom logging. On April 21, 2024, Movano Health filed an updated 510(k) for the EvieMED Ring's pulse oximetry feature. At the time of the filing and based on prior interactions with the agency and its protoco

Conference Call at 2:00 PM PT/ 5:00 PM ET PLEASANTON, Calif., Aug. 5, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced that it will report second quarter 2024 financial and operating results on Wednesday, August 14, 2024, after the market close. Management will host a conference call and live audio webcast to discuss these results and provide a business update on the same day at 2:00 pm PT/5:00 pm ET. Attendees can access the live webcast here or on the investors section of Movano Health's website at https://ir.movano.com. The c

Submits exemplary Sp02 clinical trial results as part of FDA 510(k) clearance processPlans launch of Evie Med and focuses on B2B opportunitiesPlans arterial blood pressure study for JuneConference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., May 15, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported first quarter 2024 results and provided a business update. Following the successful close of its recent $24 million private placement that included a seed investment from a tier 1 multi-billion dollar medical device company, Movan

Conference Call at 2:00 PM PT/ 5:00 PM ET PLEASANTON, Calif., May 6, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced that it will report first quarter 2024 financial and operating results on Wednesday May 15, 2024, after the market close. Management will host a conference call and live audio webcast to discuss these results and provide a business update on the same day at 2:00 pm PT/5:00 pm ET. Attendees can access the live webcast here or on the investors section of Movano Health's website at https://ir.movano.com. The confere

Financing included a strategic seed investment by a tier-1 multi-billion dollar medical device company and participation from members of Movano Health's management team and board of directors Hosting conference call on April 4, 2024 at 2:00 PM PT/5:00 PM ET PLEASANTON, Calif., April 2, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today has agreed to sell approximately 45 million units in a $24 million private placement, with each unit consisting of one share of the Company's common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase a share of common stock, to a select group of investors that includes a tier-one multi-billion dolla

Conference Call at 2:00 PM PT/ 5:00 PM ET PLEASANTON, Calif., April 2, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced that it will report fourth quarter 2023 financial and operating results on Thursday, April 4, 2024, after the market close. Management will host a conference call and live audio webcast to discuss these results and provide a business update on the same day at 2:00 pm PT/5:00 pm ET. Attendees can access the live webcast here or on the investors section of Movano Health's website at https://ir.movano.com. The con

PLEASANTON, Calif., Aug. 8, 2023 /PRNewswire/ -- Movano Inc. (NASDAQ:MOVE) dba Movano Health, a purpose-driven healthcare solutions company at the intersection of medtech and consumer devices and makers of the Evie Ring, today announced that it will report second quarter 2023 financial and operating results on Monday, August 14, 2023. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 2:00 p.m. PDT (5:00 p.m. EDT).  Attendees can access the live webcast here or on the investors section of Movano Health's webs

Conference call begins at 2:00 p.m. Pacific time today PLEASANTON, Calif., Nov. 14, 2022 /PRNewswire/ -- Today, Movano Inc. (NASDAQ:MOVE) dba Movano Health, a purpose-driven healthcare solutions company at the intersection of medical and consumer devices, reported financial results for the three months ending September 30, 2022 and provided a business update. Highlights from the third quarter and recent weeks include the following: Movano Health continues to expect to test the wearability and functionality of its smart device in beta programs with multiple strategic partners b

SC 13G - Movano Inc. (0001734750) (Subject)

SC 13G/A - Movano Inc. (0001734750) (Subject)

SC 13G - Movano Inc. (0001734750) (Subject)

SC 13G - Movano Inc. (0001734750) (Subject)

4 - Movano Inc. (0001734750) (Issuer)

4 - Movano Inc. (0001734750) (Issuer)

4 - Movano Inc. (0001734750) (Issuer)

4 - Movano Inc. (0001734750) (Issuer)

4 - Movano Inc. (0001734750) (Issuer)

4 - Movano Inc. (0001734750) (Issuer)

4 - Movano Inc. (0001734750) (Issuer)

4 - Movano Inc. (0001734750) (Issuer)

4 - Movano Inc. (0001734750) (Issuer)

4 - Movano Inc. (0001734750) (Issuer)